BioNTech is trading 4.05% down at $87.03 as broader markets sell off sharply. - Biotech ETF XBI is down 5.19%, alongside steep losses in major U.S. indexes, pointing to risk-off sentiment rather than a confirmed company-specific catalyst. - Recent earnings were strong, but the revenue beat included a one-time €613 million collaboration milestone; analysts also trimmed price targets. - The BNT113 trial setback was previously reported, not a new November 5 announcement.